COVID-19: Germany to start tests on virus vaccine


The vaccine researchers are prioritising the recruitment of local healthcare workers into the trial as they are more likely than others to be exposed to the virus. "The approval is result of a careful assessment of the potential risk/benefit profile of the vaccine candidate".

The World Health Organisation (WHO) said there are about 20 different potential COVID-19 vaccines now in development.

This vaccine, referred to as BNT162b1 by the developers, is a so-called RNA vaccine, which means that it contains an mRNA strand that is the code for a disease-specific antigen. In the body, this information is used to produce proteins against which the body's immune system then forms antibodies, according to reports.

What does the trial entail? In the second part of the trial, more people will participate, including those who are at high risk for the infection.

"Considering the serious consequences of the COVID-19 pandemic, this is a significant step toward developing an efficacious and safe COVID-19 vaccine available in Germany and making it available worldwide as soon as possible", the Paul Ehrlich Institute said in a statement. An amount of £ 25 million is being made available to the Imperial College in London for vaccine trials.

There are also plans for a possible vaccine to be tested in the UNITED states, but it has not yet been approved.

Facebook tool will track coronavirus symptoms across the UK
The maps also will include anonymized data provided by other partners, including Quidel Corp. and a national health care provider. Every day, a new sample of Facebook users over 18 years old within the United States are invited to participate in the survey.

The minister said an estimated 45 billion baht (1.39 billion USA dollars) for the vaccine research will be part of the 1.9 trillion baht (58.7 billion US dollars) loan granted by the government.

According to Dr Ikram, the benefit from the clinical trials being held in Pakistan will be that if the vaccine proves to be successful, the country will be able to procure it on a high-priority basis.

As with any drug in development, it has to be subjected to vital in vitro and animal tests before entering clinical trials.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Covid-19 Oxford Vaccine Trial request to trial a vaccine to prevent Covid-19 in a little over one working week.

Britain's Oxford University and Germany's Federal Institute will test Corona vaccines on 510 and 200 healthy people repectively. The study will also evaluate the effects of repeated immunization for three of the four vaccine candidates which utilize uRNA or modRNA.